Recent advances in partial cellular reprogramming using OSKM factors show promise in extending healthspan and treating age-related diseases, with biotech firms accelerating towards human trials. New r...
Biotech advancements in thymus regeneration, like TECregen’s therapies, show promise in rejuvenating immune function for aging populations, addressing delivery challenges and ethical considerati...
A new study demonstrates that CAR regulatory T cells targeting oxidized LDL can cut atherosclerotic plaque by 70% in mice, offering a potential one-time therapy for cardiovascular disease prevention. ...
Eli Lilly’s AI collaborations via TuneLab cut preclinical timelines by up to 30% and reduce attrition rates, democratizing drug discovery for smaller firms with enhanced data privacy. Eli Lilly&...
Artificial intelligence is accelerating drug discovery for rare diseases, reducing costs by up to 50% and shortening timelines, enabling bespoke therapies and improving healthcare equity globally. AI ...
A recent pilot study explores the safety and efficacy of intravenous BPC-157 in humans, showing potential for muscle and tendon repair with minimal side effects. A groundbreaking pilot study on intrav...
A pilot study confirms the safety of intravenous BPC-157 in humans, with potential applications in sports medicine and rehabilitation. New human data suggests intravenous BPC-157 may be safe, opening ...
A recent pilot study highlights the safety of intravenous BPC-157 in humans, reinforcing its potential for treating musculoskeletal injuries and accelerating tissue repair. New research validates the ...
